Effect of Anamorelin on Cachexia in Advanced NSCLC

June 18, 2015
Jennifer S. Temel, MD

Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.